Literature DB >> 25491938

Lupus nephritis in Egyptian children: a 16-year experience.

Atef Elmougy1, Amr Sarhan2, Ayman Hammad2, Ahmed El-Refaey2, Mohammed Zedan2, Riham Eid2, Wafaa Laimon, Wafaa Limon2, Ashraf Abd Elrahman3, Fatma Elhussieni4, Enas El-Sherbeny5, Ashraf Bakr2.   

Abstract

We retrospectively evaluated the clinical features, histo-pathological patterns, treatment modalities, and outcome of children and adolescents with lupus nephritis (LN), followed-up in Lupus Clinic, Pediatric Nephrology Unit, Mansoura University Children's Hospital between January 1997 and December 2012. Out of 194 patients diagnosed with systemic lupus erythematosus (SLE), LN was reported in 136 (70 %) patient, they were 27 males (20 %) and 109 females (80 %). The mean age at presentation was 12.5 ± 2.9 years, the mean duration of follow up was 4.1 years (range 2 months-12 years). Hematuria was present in 79 patients (58 %), proteinuria in 126 (92.6 %), 38 of them were in nephrotic range, while renal impairment was documented in 20 patients (15 %). Renal biopsy was done in 132 patients; diagnosis of class II, III, IV, V were 23, 25, 39, and 2 % respectively. Second renal biopsy was indicated in 58 patients (insufficient first biopsy 2, follow up in 45, lupus flare in 8, no response to therapy in 3 patients), while the third one was needed in only eight patients. Steroids were the commonest initial medications; used in 128 patients (63 alone and 65 with others) and cyclophosphamide was used in 64 patients. At the last follow-up visit; 19 % of patients lost follow-up, 45 % had complete remission, 21 % still had active disease, 1 % had end-stage renal disease, and 11 % died. In conclusion, in Egypt, childhood SLE is associated with frequent and severe nephritis at presentation, and this may be attributed to genetic, ethnic, or environmental factors.

Entities:  

Keywords:  Children; Egypt; Lupus nephritis; Renal biopsy; Systemic lupus erythematosus

Mesh:

Year:  2014        PMID: 25491938     DOI: 10.1007/s40620-014-0157-x

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  41 in total

1.  Increasing incidence of childhood class V lupus nephritis.

Authors:  J M Sorof; M D Perez; E D Brewer; E P Hawkins; R W Warren
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

2.  Lupus nephritis in children: prognostic significance of clinicopathological findings.

Authors:  S Emre; I Bilge; A Sirin; I Kilicaslan; A Nayir; F Oktem; V Uysal
Journal:  Nephron       Date:  2001-02       Impact factor: 2.847

3.  Serological markers in Arabs with lupus nephritis.

Authors:  H M Al Attia; Y H Al Ahmed; A U Chandani
Journal:  Lupus       Date:  1998       Impact factor: 2.911

4.  Lupus nephritis in Lebanon.

Authors:  I W Uthman; A A Muffarij; W A Mudawar; F W Nasr; A F Masri
Journal:  Lupus       Date:  2001       Impact factor: 2.911

5.  Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents.

Authors: 
Journal:  Pediatrics       Date:  1996-10       Impact factor: 7.124

6.  Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study.

Authors:  B Bader-Meunier; J B Armengaud; E Haddad; R Salomon; G Deschênes; I Koné-Paut; T Leblanc; C Loirat; P Niaudet; J C Piette; A M Prieur; P Quartier; F Bouissou; M Foulard; G Leverger; I Lemelle; P Pilet; M Rodière; N Sirvent; P Cochat
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

7.  Ethnic differences in risk for pediatric rheumatic illness in a culturally diverse population.

Authors:  David Kurahara; Angela Tokuda; Andrew Grandinetti; Julie Najita; Carolyn Ho; Kara Yamamoto; D Venu Reddy; Katherine Macpherson; Mildred Iwamuro; Karen Yamaga
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

8.  Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis.

Authors:  R Abdwani; S G Rizvi; I El-Nour
Journal:  Lupus       Date:  2008-07       Impact factor: 2.911

9.  Systemic lupus erythematosus in Kuwaiti children: organ system involvement and serological findings.

Authors:  K Alsaeid; H Kamal; M Z Haider; H M Al-Enezi; A N Malaviya
Journal:  Lupus       Date:  2004       Impact factor: 2.911

10.  Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.

Authors:  N Baqi; S Moazami; A Singh; H Ahmad; S Balachandra; A Tejani
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

View more
  5 in total

Review 1.  Management and outcomes in children with lupus nephritis in the developing countries.

Authors:  Priyanka Khandelwal; Srinivasavaradan Govindarajan; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2022-10-18       Impact factor: 3.651

2.  Childhood lupus nephritis: 12 years of experience from a developing country's perspective.

Authors:  Moumita Samanta; Madhumita Nandi; Rakesh Mondal; Avijit Hazra; Sumatra Sarkar; Tapas Sabui; Chanchal Kumar Kundu; Arnab Biswas
Journal:  Eur J Rheumatol       Date:  2017-09-01

3.  Mast cells in the kidney biopsies of pediatric patients with lupus nephritis.

Authors:  Stéfany Silva Santos; Carolina Marques Ramos; Maria Luiza Gonçalves Dos Reis Monteiro; Juliana Reis Machado; Marlene Antônia Dos Reis; Rosana Rosa Miranda Corrêa; Laura Penna Rocha
Journal:  J Bras Nefrol       Date:  2020-01-31

4.  Clinicopathological findings and outcome of lupus nephritis in Tunisian children: a review of 43 patients.

Authors:  Hela Jebali; Meriam Hajji; Lamia Rais; Fethi Ben Hamida; Soumaya Beji; Mohammed Karim Zouaghi
Journal:  Pan Afr Med J       Date:  2017-06-30

5.  Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis.

Authors:  Abdulaziz Almutairi; Ziyad Alkathiri; Sulaiman M Al-Mayouf
Journal:  Int J Pediatr Adolesc Med       Date:  2018-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.